Response to Trametinib of a Pulmonary Langerhans Cell Histiocytosis Harboring a MAP2K1 Deletion

被引：26
|
作者：
Lorillon, Gwenael [1 ]
Jouenne, Fanelie [1 ,2 ]
Baroudjian, Barouyr [1 ]
de Margerie-Mellon, Constance [1 ,2 ]
Vercellino, Laetitia [1 ]
Meignin, Veronique [1 ,3 ]
Lebbe, Celeste [1 ,2 ,4 ]
Vassallo, Robert [5 ]
Mourah, Samia [1 ,2 ,4 ]
Tazi, Abdellatif [1 ,2 ,6 ]
机构：
[1] AP HP, Paris, France
[2] Univ Paris Diderot, Paris, France
[3] INSERM, UMR S1165, Paris, France
[4] INSERM, U976, Paris, France
[5] Mayo Clin, Rochester, MN USA
[6] CRESS, U1153, Paris, France
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2018年 / 198卷 / 05期
关键词：
ERDHEIM-CHESTER DISEASE; MUTATIONS; VEMURAFENIB; ACTIVATION;
D O I：
10.1164/rccm.201802-0275LE
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
引用
收藏
页码：675 / 678
页数：4
相关论文
共 50 条
  • [41] Co-occurrence of targetable aberrations in non-small cell lung cancer patients harboring MAP2K1 mutations.
    Holzem, Alessandra
    Nogova, Lucia
    Ihle, Michaela A.
    Wompner, Claudia
    Bitter, Elisabeth
    Michels, Sebastian Yves Friedrich
    Fischer, Rieke Nila
    Kron, Anna
    Gerigk, Ulrich
    Kern, Jens
    Kaminsky, Britta
    Randerath, Winfried
    Lorenz, Joachim
    Kambartel, Karl-Otto
    Merkelbach-Bruse, Sabine
    Buttner, Reinhard
    Scheffler, Matthias
    Wolf, Juergen
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [42] Co-occurrence of targetable mutations in Non-small cell lung cancer (NSCLC) patients harboring MAP2K1 mutations
    Scheffler, Matthias
    Holzem, Alessandra
    Kron, Anna
    Nogova, Lucia
    Ihle, Michaela A.
    von Levetzow, Cornelia
    Fassunke, Jana
    Woempner, Claudia
    Bitter, Elisabeth
    Koleczko, Sophia
    Abdulla, Diana S. Y.
    Michels, Sebastian
    Fischer, Rieke
    Riedel, Richard
    Weber, Jan-Philipp
    Westphal, Theresa
    Gerigk, Ulrich
    Kern, Jens
    Kaminsky, Britta
    Randerath, Winfried
    Kambartel, Karl-Otto
    Merkelbach-Bruse, Sabine
    Buttner, Reinhard
    Wolf, Juergen
    LUNG CANCER, 2020, 144 : 40 - 48
  • [43] MAP2K1-MUTATED ECD/RDD-OVERLAP NON-LANGERHANS CELL HISTIOCYTOSIS RESPONDING TO COBIMETINIB
    Classen, Carl Friedrich
    Leyh, Joerg
    Ruemmele, Petra
    Rosenwald, Andreas
    Metzler, Markus
    PEDIATRIC BLOOD & CANCER, 2021, 68
  • [44] Somatic activating mutations in MAP2K1 cause melorheostosis
    Heeseog Kang
    Smita Jha
    Zuoming Deng
    Nadja Fratzl-Zelman
    Wayne A. Cabral
    Aleksandra Ivovic
    Françoise Meylan
    Eric P. Hanson
    Eileen Lange
    James Katz
    Paul Roschger
    Klaus Klaushofer
    Edward W. Cowen
    Richard M. Siegel
    Joan C. Marini
    Timothy Bhattacharyya
    Nature Communications, 9
  • [45] Endothelial cell expression of mutant Map2k1 causes vascular malformations in mice
    Patrick J. Smits
    Christopher L. Sudduth
    Dennis J. Konczyk
    Yu Sheng Cheng
    Matthew P. Vivero
    Harry P. W. Kozakewich
    Matthew L. Warman
    Arin K. Greene
    Angiogenesis, 2023, 26 : 97 - 105
  • [46] Endothelial cell expression of mutant Map2k1 causes vascular malformations in mice
    Smits, Patrick J.
    Sudduth, Christopher L.
    Konczyk, Dennis J.
    Cheng, Yu Sheng
    Vivero, Matthew P.
    Kozakewich, Harry P. W.
    Warman, Matthew L.
    Greene, Arin K.
    ANGIOGENESIS, 2023, 26 (01) : 97 - 105
  • [47] Arteriovenous malformation Map2k1 mutation affects vasculogenesis
    Christopher L. Sudduth
    Patrick J. Smits
    Matthew P. Vivero
    Yu Sheng Cheng
    Michal Ad
    Dennis J. Konczyk
    Joyce Bischoff
    Matthew L. Warman
    Arin K. Greene
    Scientific Reports, 13
  • [48] E203K mutation in MAP2K1 (MEK1) causes acquired resistance to PD-1 blockade but responds to trametinib: a case report
    Leng, Weibing
    Wei, Guixia
    Sheng, Leiming
    Jiang, Dan
    Qiu, Meng
    CHINESE CLINICAL ONCOLOGY, 2024, 13 (06)
  • [49] Oncogenic MAP2K1 mutations in human epithelial tumors
    Choi, Young Lim
    Soda, Manabu
    Ueno, Toshihide
    Hamada, Toru
    Haruta, Hidenori
    Yamato, Azusa
    Fukumura, Kazutaka
    Ando, Mizuo
    Kawazu, Masahito
    Yamashita, Yoshihiro
    Mano, Hiroyuki
    CARCINOGENESIS, 2012, 33 (05) : 956 - 961
  • [50] Somatic activating mutations in MAP2K1 cause melorheostosis
    Kang, H.
    Jha, S.
    Deng, Z.
    Fratzl-Zelman, N.
    Cabral, W. A.
    Ivovic, A.
    Meylan, F.
    Hanson, E. P.
    Lange, E.
    Katz, J.
    Roschger, P.
    Klaushofer, K.
    Cowen, E. W.
    Siegel, R. M.
    Bhattacharyya, T.
    Marini, J. C.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 822 - 823
12345